ArticleIranian journal of biotechnology2026
Application Value of Multi-Gene Testing in the Evaluation of Benign and Malignant Thyroid Nodules.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid nodules are highly prevalent in clinical practice, and accurate preoperative distinction between benign and malignant lesions remains a major diagnostic challenge. Objective: This study aims to explore the variation of multi-gene detection in benign and malignant thyroid nodules and the application value of combining the 2023 Bethesda System for Reporting Thyroid Cytopathology (BSRTC) in evaluating the benign and malignant nature of thyroid nodules. Materials and Methods: A total of 593 patients with thyroid nodules (total 697 nodules) underwent ultrasound-guided fine-needle aspiration biopsy were collected from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. All of them were subjected to cytological examination and multi-gene testing, 247 had histopathological results. The next-generation sequencing platform was applied for multi-gene testing. A panel of well-recognized commonly mutated genes in thyroid cancer were analyzed, including BRAF, HRAS, KRAS, NRAS, TP53, TERT, RET, NTRK1, NTRK3, PAX8, THADA. Results: Gene mutations were identified in 226 nodules (226/247; 91.5%), with BRAF being the most prevalent driver gene alteration observed in this cohort (193/226; 85.4%), followed by RAS (26/226, 11.5%). The overall malignancy rate of gene mutations was 97.3% in our cohort, of which the lymph node metastasis rate was 43.8%. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the combined application of multi-gene testing and cytology were 99.5%, 92.9%, 99.5%, 92.9%, and 93.1%, respectively. The sensitivity and negative predictive value of the combined application were higher than those of cytology, the differences were statistically significant (P<0.05). Conclusions: Multi-gene testing could substantially enhance the detection rate of malignant thyroid nodules and protect patients with benign nodules from unnecessary surgeries. The combined application of multi-gene testing and cytology can achieve more precise diagnosis and risk stratification of thyroid nodules. It provides a valuable reference for individualized preoperative decision-making, which may serve as a crucial method for postoperative treatment and prognosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.